Clinical Study
Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice
Table 3
Associations with discontinuation in placebo group (
).
| | Successful discontinuation (continuing placebo) () | Unsuccessful discontinuation (discontinuing placebo) () | value |
| Age median (IQR), year | 58 (48–62) | 60 (51–69) | 0.81 | Male (%) | 23% | 58% | 0.003 | Helicobacter pylori-positive, % (95% CI) | 29 (12–51) | 17 (8–29) | 0.24 | No nicotine use, % (95% CI) | 68 (46–85) | 50 (37–63) | 0.12 | Alcohol use, <21 units/weeks, % (95% CI) | 92 (74–99) | 92 (82–97) | 0.96 | Symptom duration, median (10%; 90%) percentile, year | 4 (0–13) | 4 (1–14) | 0.21 | Previous endoscopy, % (95% CI) | 40 (21–61) | 47 (24–60) | 0.58 | Previous NSAID/ASA use, % (95% CI) | 60 (39–79) | 62 (48–74) | 0.89 | GSRS total, mean (95% CI) | 2.5 (2.2–2.8) | 2.9 (2.5–3.2) | 0.07 | GSRS reflux score, mean (95% CI) | 3.0 (2.5–3.5) | 3.3 (2.9–3.8) | 0.29 | SF-36 physical health summary score, mean score (95% CI) | 41 (36–46) | 43 (40–46) | 0.54 | SF-36 mental health summary score, mean score (95% CI) | 48 (42–54) | 51 (49–54) | 0.20 |
|
|
-test for linear regression.
|